Media
View our latest materials to follow our progress in tackling respiratory diseases.
Latest Videos
View all videos
Filters
Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update
LONDON, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for the full year ended December 31, 2019 on Thursday,
Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research
Paper demonstrates ensifentrine’s potential in improving lung function and quality of life symptoms
Holding(s) in Company TR-1: Standard form for notification of major holdings
LONDON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings
Verona Pharma Announces Senior Management Changes
LONDON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., has been appointed President and Chief Executive Officer (CEO) with effect from February 1, 2020.
Verona Pharma to Present at LSX World Congress 2020
LONDON, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Piers Morgan, CFO of Verona Pharma, will present a corporate overview and host one-on-one meetings at the LSX World Congress taking place in London on February 4-5, 2020.
Holding(s) in Company TR-1: Standard form for notification of major holdings
LONDON, Jan. 17, 2020 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings
Verona Pharma
Investor Information
© Verona Pharma plc 2020. All rights reserved